Researchers at the University of Pennsylvania identified a molecule that reversed memory deficits in mice engineered to show Alzheimer's-like symptoms, according to a study published this week in the journal Aging Biology. [1] The molecule, 4-phenylbutyrate, acts as a "chemical chaperone" that prevents misfolded proteins from clumping and damaging brain cells. [1]

Before treatment, the mice failed standard memory tests, unable to distinguish objects that had been moved from ones left in place. [1] After receiving PBA, even at advanced stages of disease, the mice showed a marked recovery in those same tests. "By generally improving neuronal and cellular health, we can mitigate or delay disease progression," said Nirinjini Naidoo, the study's lead author and an associate professor of sleep medicine research. [1]

The result is genuinely notable: most Alzheimer's research targets slowing decline, not restoring lost function. But the study is preclinical, tested only in mice, and the researchers were explicit that "there is still much to accomplish before clinical applications in humans are possible." [1] That caveat sits at the bottom of most coverage, well below headlines describing the molecule as a "breakthrough." It is the same pattern that has undercut a string of mouse-model Alzheimer's findings before it — real laboratory results that readers are left to translate into false hope of a human treatment on their own.

-- NORA WHITFIELD, Chicago